%0 Journal Article
%A Langenberg, Karin P S
%A van Hooff, Sander R
%A Koopmans, Bianca
%A Strijker, Josephine G M
%A Kholosy, Waleed M
%A Ober, Kimberley
%A Zwijnenburg, Danny A
%A van der Hoek, Jessica J F
%A Keller, Kaylee M
%A Vernooij, Lindy
%A Schild, Linda G
%A Looze, Eleonora J
%A Ebus, Marli E
%A Essing, Anke H W
%A Vree, Paula de
%A Tas, Michelle L
%A Matser, Yvette A H
%A Wienke, Judith
%A Volckmann, Richard
%A Tops, Bastiaan B J
%A Kester, Lennart A
%A Badloe, Shashi
%A Hehir-Kwa, Jayne Y
%A Kemmeren, Patrick
%A Goemans, Bianca F
%A Zwaan, C Michel
%A Oehme, Ina
%A Jäger, Nathalie
%A Witt, Olaf
%A van Eijkelenburg, Natasha K A
%A Dierselhuis, Miranda P
%A Tytgat, Godelieve A M
%A Wijnen, Marc H W
%A van Noesel, Max M
%A de Krijger, Ronald R
%A Eising, Selma
%A Koster, Jan
%A Dolman, Emmy M
%A Molenaar, Jan J
%T Exploring high-throughput drug sensitivity testing in neuroblastoma cell lines and patient-derived tumor organoids in the era of precision medicine.
%J European journal of cancer
%V 218
%@ 0959-8049
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2025-00363
%P 115275
%D 2025
%X Despite druggable events to be present in 80 
%K Adolescent (Other)
%K Cancer (Other)
%K Child (Other)
%K High-throughput drug screening (Other)
%K Molecular biology (Other)
%K Molecular targeted therapy (Other)
%K Neuroblastoma (Other)
%K Next-generation sequencing (Other)
%K Organoid (Other)
%K Precision medicine (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:39954414
%R 10.1016/j.ejca.2025.115275
%U https://inrepo02.dkfz.de/record/298929